SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Atlas Venture Associates IX, LLC

CIK 0001671207 · 56 WAREHAM STREET, FLOOR 3, BOSTON, MA, 02118 · 617-588-2694

Reported Value
$94M
Q2 2019
Positions
7
Filings on Record
19
2019–present window
Filed
Aug 6, 2019
original filing

Summary

Atlas Venture Associates Ix, LLC reported $94M in U.S.-listed holdings across 7 positions for Q2 2019.

The portfolio is heavily concentrated: NTLA alone accounts for 28.3% of reported value.

The book was largely unchanged from Q1 2019.

Portfolio Metrics

Turnover
+5.0%
vs prior filed quarter
Largest Position
+28.3%
Intellia Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $106MQ1 ’19Q2 ’19: $94MQ3 ’19: $61MQ4 ’19: $57MQ4 ’19Q1 ’20: $47MQ2 ’20: $94MQ3 ’20: $97MQ3 ’20Q4 ’20: $631MQ1 ’21: $595MQ2 ’21: $568MQ2 ’21Q3 ’21: $301MQ4 ’21: $229MQ1 ’22: $109MQ1 ’22Q2 ’22: $44MQ3 ’22: $34MQ4 ’22: $20MQ4 ’22Q1 ’23: $21MQ2 ’23: $18MQ3 ’23: $12MQ3 ’23filingsflow.com

Portfolio Composition

By security type
Common Stock: 61.5%Other: 38.5%
  • Common Stock · 61.5% · $58M
  • Other · 38.5% · $36M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SURFACE ONCOLOGY INCHELD+04.65M$9M$13M
UNUM THERAPEUTICS INCHELD+03.36M$6M$9M
SYNLOGIC INCHELD+02.65M+$4M$24M
SPROSPERO THERAPEUTICS INCHELD+01.38M$2M$16M
NTLAINTELLIA THERAPEUTICS INCHELD+01.62M$1M$26M
CARBON BLACK INCHELD+0181.3K+$502,000$3M
SNAPSNAP INCHELD+0150.2K+$492,000$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

7 positions
#IssuerClass% PortfolioValueShares
1NTLAINTELLIA THERAPEUTICS INChistory →COM28.28%$26M1.62M
2SYNLOGIC INCCOM25.81%$24M2.65M
3SPROSPERO THERAPEUTICS INChistory →COM16.95%$16M1.38M
4SURFACE ONCOLOGY INCCOM14.01%$13M4.65M
5UNUM THERAPEUTICS INCCOM9.42%$9M3.36M
6CARBON BLACK INCCOM3.24%$3M181.3K
7SNAPSNAP INChistory →CL A2.30%$2M150.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2023$12M6Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$18M6Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$21M6May 8, 202313F-HRchanges · EDGAR ↗
Q4 2022$20M6Jan 31, 202313F-HRchanges · EDGAR ↗
Q3 2022$34M6Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$44M7Aug 11, 202213F-HRchanges · EDGAR ↗
Q1 2022$109M7May 12, 202213F-HRchanges · EDGAR ↗
Q4 2021$229M7Jan 27, 202213F-HRchanges · EDGAR ↗
Q3 2021$301M7Nov 4, 202113F-HRchanges · EDGAR ↗
Q2 2021$568M7Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$595M7May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$631M7Feb 3, 202113F-HRchanges · EDGAR ↗
Q3 2020$97M6Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$94M6Aug 6, 202013F-HRchanges · EDGAR ↗
Q1 2020$47M6May 7, 202013F-HRchanges · EDGAR ↗
Q4 2019$57M6Feb 11, 202013F-HRchanges · EDGAR ↗
Q3 2019$61M7Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$94M7Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$106M7May 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.